Vedolizumab
Brand name: Entyvio
Rank #449 of 500 drugs by total cost
$17.4M
Total Cost
2,034
Total Claims
$17.4M
Total Cost
119
Prescribers
$8,531
Cost per Claim
0
Beneficiaries
2,894
30-Day Fills
$146K
Avg Cost/Provider
17
Avg Claims/Provider
About Vedolizumab
Vedolizumab (sold as Entyvio) was prescribed 2,034 times by 119 Medicare Part D providers in 2023, costing the program $17.4M. At $8,531 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 446 | Vismodegib (Erivedge) | $17.4M | 1,317 |
| 447 | Anastrozole (Anastrozole) | $17.4M | 626,025 |
| 448 | Naproxen (Naproxen) | $17.4M | 903,928 |
| 449 | Vedolizumab (Entyvio) | $17.4M | 2,034 |
| 450 | Abatacept/Maltose (Orencia) | $17.2M | 3,809 |
| 451 | Potassium Citrate (Potassium Citrate Er) | $17.1M | 131,481 |
| 452 | Insulin Degludec/Liraglutide (Xultophy 100-3.6) | $17.1M | 10,644 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology